• Recruiting

NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM

Updated: May 25

IFM2021_03


NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." (I2D IFM2021_03)


ifm2021

Sponsor

Nantes University Hospital


This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse .


The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria.


Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.

 

ClinicalTrials.gov Identifier: NCT04998786


Official Title: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."


First Posted : August 10, 2021


Click here to see details on ClinicalTrials.gov

2021-001587-13 ( EudraCT Number )


https://www.myelome.fr/

 

Drug: Ixazomib

Drug: Iberdomide

Drug: Dexamethasone Oral

 

Location

Europe

France





Posts Archive